Science Innovations: Natural Rainbow Colours Produced  |  Technology Inceptions: Muscope, World’s Smallest Microscope  |  Science Innovations: Ultrasensitive Tactile Sensors for Robots  |  Policy Indications: How Materials Science Helps Contain Contain Covid-19 Spread  |  National Edu News: IIT Hyderabad and PharmCADD signed a pact for the co-development of new drugs   |  Teacher Insights: Be Game  |  Health Monitor: Understanding ‘Haemorrhage'  |  National Edu News: Pallikkutam GlobalConnect#3 on 'Innovative Tools for Effective Teaching'  |  Expert Counsel: The Nine Dash Line  |  National Edu News: Astronomers Find One Group of Appearing and Disappearing Stars  |  Teacher Insights: Bird Book for Children to Love Nature  |  International Edu News: New Model to Fight Social Media Deep Fakes  |  Teacher Insights: Universal Lunch Makes Students Healthier  |  Teacher Insights: Physical Activity Boosts Self Regulation  |  Parent Interventions: Anti-Inflammatory Foods Reduce Blood Fats  |  
February 24, 2020 Monday 03:48:25 PM IST

Cough syrup drug being trialled as Parkinson’s treatment

Science Innovations

Ambroxol, a medication originally designed to clear phlegm and ease coughing for people with respiratory diseases such as bronchitis, is being tested to see if it can slow down the progression of Parkinson’s disease by keeping cells healthier for longer. A research team led by Professor Tony Schapira (UCL Queen Square Institute of Neurology) reported in January that ambroxol was safe and well-tolerated in 17 study participants with Parkinson’s disease.

According to the findings published in JAMA Neurology, the drug also effectively crossed the blood-brain barrier and increased levels of the glucocerebrosidase (GCase) protein in the participants’ brain cells. This protein allows cells to remove waste more effectively, a function which evidence suggests is deficient in some people with Parkinson’s. Increasing levels of the protein may have the potential to keep cells healthier for longer and, therefore, slow Parkinson’s progression.

This month week, The Cure Parkinson’s Trust (CPT), the Van Andel Institute (VAI) and the John Black Charitable Foundation announced £522,126 of funding for the next stage of the research, which will seek to determine the optimal dosage of ambroxol. The trial will be run this year at the Leonard Wolfson Experimental Neurology Centre at UCL and led by Professor Schapira, with the aim of leading to a larger clinical trial later on.

The announcement comes as part of a USD $4.5 million co-funding agreement with the Van Andel Institute (VAI) to support the International Linked Clinical Trials (iLCT) initiative. iLCT is a thriving global programme that aims to develop new, potentially disease-modifying Parkinson’s therapies, many of which are repurposed medications originally designed or approved to treat other diseases.


Candidate drugs are evaluated and prioritised annually by a committee of world-leading Parkinson’s experts, who select which drugs should enter clinical trials in people with the condition. These drugs have the potential to get to the clinic much faster as they have already passed crucial safety tests.


(Content and Image Courtesy: https://www.ucl.ac.uk/news/2020/feb/cough-syrup-drug-being-trialled-parkinsons-treatment)


Comments